Evidence map›Paper›PMID 38392047›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report.

Claudia De Intinis, Paolo Izzo, Massimo Codacci-Pisanelli, Luciano Izzo, Daniela Messineo, Simone Sibio, Monica Campagnol, Silvia Lai, Marcello Molle, Sara Izzo

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Claudia De IntinisDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0001-5500-0268
Paolo IzzoDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-4702-5171
Massimo Codacci-PisanelliDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Luciano IzzoDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0001-7852-032X
Daniela MessineoDepartment of Radiological Sciences, Oncology and Anatomo-Pathological Science, "Sapienza" University of Rome, Viale dell'Universitá 31/33, 00161 Rome, Italy.ORCID 0000-0003-3059-4439
Simone SibioDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-5694-951X
Monica CampagnolDepartment of Surgery "Pietro Valdoni", Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Silvia LaiDepartment of Translational and Precision Medicine, Nephrology Unit, "Sapienza" University of Rome, Viale dell'Universitá 31/33, 00161 Rome, Italy.ORCID 0000-0002-7199-2954
Marcello MolleMultidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 1, 80138 Naples, Italy.ORCID 0009-0009-5901-2659
Sara IzzoMultidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Luigi Miraglia 1, 80138 Naples, Italy.
Policlinico Umberto I · ITSapienza University of Rome · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

introductionLung cancer is a prevalent and deadly disease globally. Non-small cell lung cancer (NSCLC) is the most common subtype, comprising 85% of cases. CASE REPORT: A 65-year-old male ex-smoker presented to our facility with a nocturnal cough. Various investigations revealed that he had metastatic NSCLC, for which he underwent chemotherapy with cisplatin and gemcitabine, followed by immunotherapy with Nivolumab. He achieved a complete response to the therapy and has remained free from recurrence for over 7 years since the initial diagnosis. DISCUSSION AND

conclusionsThe treatment of metastatic NSCLC remains a significant therapeutic challenge, but the implementation of new therapeutic techniques has expanded the possibilities of achieving complete and durable eradication of the disease.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedDisease-Free SurvivalHumansImmunotherapyMaleNivolumabNivolumabcase reportcomplete responseimmunotherapyliterature reviewmetastasisNSCLC

Identifiers

PMID38392047
PMCPMC10888175
OpenAlexW4391383797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.